Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80

Product › Details

BI 1467335 (PXS-4728A) (Boehringer / Pharmaxis)

	Next higher product group	semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor
	Status	2018-08-06 development p2 existent
	Organisation	Boehringer Ingelheim GmbH
	Group	Boehringer Ingelheim (Group)
	Organisation 2	Pharmaxis Ltd. (ASX: PXS)

Record changed: 2020-09-21

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for anti-inflammatory drug

[1] MoonLake Immunotherapeutics AG. (5/6/21). "Press Release: MoonLake Immunotherapeutics Announces Publication in The Lancet". Zug....
[2] Cytoki Pharma ApS. (5/5/21). "Press Release: Cytoki Pharma Raises $45 Million Series A Financing". Copenhagen....
[3] Eleva GmbH. (1/6/21). "Press Release: Eleva Secures up to EUR 60 Million to Advance a Drug Candidate, Appoints New Board Member". Freiburg....
[4] Galapagos N.V.. (12/15/20). "Press Release: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (filgotinib)". Foster City, CA & Mechelen....
[5] Immune Regulation Ltd.. (9/21/20). "Press Release: Immune Regulation Limited Raises £40.6 Million / $53.4 Million Series B Equity Financing". London & Boston, MA....
[6] Boehringer Ingelheim. (9/7/20). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for Diabetic Retinopathy". Ingelheim & Sydney....
[7] Galapagos N.V.. (8/19/20). "Press Release: Galapagos Announces that Gilead Received a Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis". Mechelen....
[8] Gesynta Pharma AB. (7/7/20). "Press Release: Gesynta Raises SEK 190 Million in Round Led by Hadean Ventures to Accelerate Development of First-in-class mPGES-1 Inhibitor GS-248 for Systemic Sclerosis". Stockholm....
[9] Galapagos N.V.. (4/16/20). "Press Release: Galapagos and Ryvu Announce Research Collaboration". Mechelen & Krakow....
[10] AM-Pharma B.V.. (3/31/20). "Press Release: AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI". Utrecht....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]